Lack of DayNight variation in fibroblast growth factor 21 levels in young healthy men

International Journal of Obesity

Volumn 39, Issue 6, 2015, Pages 945-948

  Foo, J P ^a   Aronis, K N ^a,b,c   Chamberland, J P ^a,b   Mantzoros, C S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR; LEPTIN;

ADULT; ARTICLE; CIRCADIAN RHYTHM; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPOLYSIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; ENERGY METABOLISM; PHYSIOLOGY; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; YOUNG ADULT;

CIRCADIAN RHYTHM; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; FIBROBLAST GROWTH FACTORS; HEALTHY VOLUNTEERS; HUMANS; LEPTIN; MALE; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; WEIGHT LOSS; YOUNG ADULT;

EID: 84930760759     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.215     Document Type: Article

References (28)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
2. Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS. Acute exercise induces FGF21 expression in mice and in healthy humans. PloS One 2013; 8: e63517.
3. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009; 106: 10853-10858.
4. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
5. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
6. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789.
7. Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169-174.
8. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58: 1532-1538.
9. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 57: 691-700.
10. Foo JP, Aronis KN, Chamberland JP, Paruthi J, Moon HS, Mantzoros CS. Fibroblast growth factor 21 levels in young healthy females display day and night variations and are increased in response to short-term energy deprivation through a leptin-independent pathway. Diabetes Care 2013; 36: 935-942.
11. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab 2011; 96: 885-893.
12. Jensen MD, Johnson CM. Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metab Clin Exp 1996; 45: 662-666.
13. Jensen MD, Cryer PE, Johnson CM, Murray MJ. Effects of epinephrine on regional free fatty acid and energy metabolism in men and women. Am J Physiol 1996; 270: E259-E264.
14. Mittendorfer B, Horowitz JF, Klein S. Gender differences in lipid and glucose kinetics during short-term fasting. Am J Physiol Endocrinol Metab 2001; 281: E1333-E1339.
15. Horton TJ, Dow S, Armstrong M, Donahoo WT. Greater systemic lipolysis in women compared with men during moderate-dose infusion of epinephrine and/or norepinephrine. J Appl Physiol 2009; 107: 200-210.
16. Zauner C, Schneeweiss B, Kranz A, Madl C, Ratheiser K, Kramer L et al. Resting energy expenditure in short-term starvation is increased as a result of an increase in serum norepinephrine. Am J Clin Nutr 2000; 71: 1511-1515.
17. Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS. Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin Endocrinol (Oxf) 2007; 66: 49-57.
18. Schlierf G, Dorow E. Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973; 52: 732-740.
19. Boyle PJ, Avogaro A, Smith L, Bier DM, Pappu AS, Illingworth DR et al. Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans. Am J Physiol 1992; 263: E168-E172.
20. Hagstrom-Toft E, Bolinder J, Ungerstedt U, Arner P. A circadian rhythm in lipid mobilization which is altered in IDDM. Diabetologia 1997; 40: 1070-1078.
21. Koutsari C, Basu R, Rizza RA, Nair KS, Khosla S, Jensen MD. Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab 2011; 96: 541-547.
22. Andersen B, Beck-Nielsen H, Hojlund K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 2011; 75: 514-519.
23. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Therapeut 2013; 346: 270-280.
24. Smith R, Duguay A, Weiszmann J, Stanislaus S, Belouski E, Cai L et al. A novel approach to improve the function of FGF21. BioDrugs 2013; 27: 159-166.
25. Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes. PloS One 2012; 7: e49345.
26. Korkmaz A, Topal T, Tan DX, Reiter RJ. Role of melatonin in metabolic regulation. Rev Endocr Metab Disord 2009; 10: 261-270.
27. Gangwisch JE, Feskanich D, Malaspina D, Shen S, Forman JP. Sleep duration and risk for hypertension in women: results from the nurses' health study. Am J Hypertens 2013; 26: 903-911.
28. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009; 106: 4453-4458.